Cyclerion Therapeutics (NASDAQ:CYCN) announced it has signed a definitive merger agreement with privately held Korsana Biosciences in an all-stock transaction, according to a company press release. The announcement comes as Cyclerion shares trade around $1.55, giving the company a market capitalization of roughly $5.9 million, with the stock down 4.3% over the past week.
Following the transaction, the merged business will operate under the name Korsana Biosciences and will trade on Nasdaq under the ticker KRSA. Current Cyclerion shareholders are expected to hold about 1.5% of the combined company, while existing Korsana investors will control approximately 98.5%.
Korsana has also secured investor commitments for a private financing expected to generate approximately $380 million in gross proceeds, led by Fairmount and Venrock Healthcare Capital Partners. The financing will include common shares and pre-funded warrants exercisable for Korsana stock and is expected to close immediately before the merger is finalized.
The companies expect that the combined entity’s cash position at closing will support operations through 2029. Korsana’s lead drug candidate, KRSA-028, is a monoclonal antibody targeting amyloid beta being developed as a treatment for Alzheimer’s disease.
The company anticipates Phase 1 data from healthy volunteers by mid-2027, followed by interim proof-of-concept results measuring amyloid plaque reduction in Alzheimer’s patients by the end of 2027.
KRSA-028 is built on the Therapeutic Targeting platform, which incorporates transferrin receptor and Fc engineering technologies designed to enhance delivery of therapies to the brain. The treatment is being developed for subcutaneous administration.
Jonathan Violin, President and Chief Executive Officer of Korsana, will serve as CEO of the combined company. The current Korsana board of directors will also form the board of the new entity, with Tomas Kiselak of Fairmount serving as chairman.
Both companies’ boards have approved the deal, which is expected to close in the third quarter of 2026, pending shareholder approval, SEC registration effectiveness, expiration of the Hart-Scott-Rodino waiting period, and other customary conditions.
Wedbush Securities is acting as financial advisor to Korsana, while Gemini Valuation Services is serving as financial advisor to Cyclerion.
In separate developments, Cyclerion recently received positive written feedback from the U.S. Food and Drug Administration regarding its planned Phase 2 proof-of-concept study of CYC-126 for treatment-resistant depression. The agency’s feedback provided clarity on the regulatory pathway and supported key elements of the proposed study design.
Cyclerion also announced a strategic partnership with Medsteer aimed at advancing its closed-loop anesthetic platform for this indication. The agreement is exclusive and application-specific, focusing on integrating Medsteer’s proprietary technology into Cyclerion’s lead program, CYC-126.
The collaboration will incorporate EEG-guided monitoring technology, enabling more precise and individualized treatment using anesthetic agents with real-time monitoring and algorithm-based dosing. These steps mark continued progress in Cyclerion’s efforts to develop therapies for treatment-resistant depression.